BNF:

8.1.5

Status:

Do Not Prescribe (DNP), Red

Decision Date:

None

Comments

DO NOT PRESCRIBE (DNP): NICE TA241: NICE does not recommend high-dose imatinib for people with Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic, accelerated or blast-crisis phase that has got worse after treatment with standard-dose imatinib.

(Imatinib can be funded through the cancer drug fund for the above indication - seek advice from the oncologist/haematologist)

RED:^1,2,3 NICE TA251: Leukaemia (chronic myeloid) - for 1st line treatment of chronic phase Philadelphia-chromosome-positive CML: Imatinib - recommended as an option (decision date - May 2012)

RED:^1,2,3 NICE TA326: for the treatment of gastrointestinal stromal tumours (decision date - December 2014)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again